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Abstract
Background: Formation of an HIV-1 particle with a conical core structure is a prerequisite for
the subsequent infectivity of the virus particle. We have previously described that glycineamide (G-
NH2) when added to the culture medium of infected cells induces non-infectious HIV-1 particles
with aberrant core structures.
Results: Here we demonstrate that it is not G-NH2 itself but a metabolite thereof that displays
antiviral activity. We show that conversion of G-NH2 to its antiviral metabolite is catalyzed by an
enzyme present in bovine and porcine but surprisingly not in human serum. Structure
determination by NMR suggested that the active G-NH2 metabolite was α-hydroxy-glycineamide
(α-HGA). Chemically synthesized α-HGA inhibited HIV-1 replication to the same degree as G-
NH2, unlike a number of other synthesized analogues of G-NH2 which had no effect on HIV-1
replication. Comparisons by capillary electrophoresis and HPLC of the metabolite with the
chemically synthesized α-HGA further confirmed that the antiviral G-NH2-metabolite indeed was
α-HGA.
Conclusion: α-HGA has an unusually simple structure and a novel mechanism of antiviral action.
Thus, α-HGA could be a lead for new antiviral substances belonging to a new class of anti-HIV
drugs, i.e. capsid assembly inhibitors.
Background
During or concomitant with the HIV-1 release from
infected cells, the Gag precursor protein (p55) is cleaved
sequentially into matrix (MA/p17), capsid (CA/p24),
nucleocapsid (NC/p7) and p6. Thus, proteolytic cleavage
of p55 within the budded particle triggers a morphologi-
cal change of the core which transforms it from a spherical
[1] to a conical core structure consisting of approximately
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1,500 p24 molecules [2-4]. The conical core formation
not only results as a consequence of the proteolytic cleav-
age of p55 but also from substantial conformational
changes and rearrangements of the p24 [1] which is con-
nected to one another through N-terminal hexamer and
C-terminal dimer formations [5-8]. Acquisition of virion
infectivity, reverse transcription, and subsequent dissocia-
tion of the capsid core are all critically dependent on just
the right semi-stability of the capsid cone structure, which
in turn is made up of multiple semi-stable non-covalent
p24-p24 interactions [9]. Thus, proper structural rear-
rangement of p24 after Gag cleavage is a crucial step and
is a highly conserved feature in most retroviruses [10].
This makes p24 of interest as a target for developing new
antiviral drugs.
There are twenty-five approved drugs that belong to six
different antiretroviral classes for the treatment of HIV-
patients [11]. The majority of these drugs control HIV-1
infection by targeting the two viral enzymes reverse tran-
scriptase and protease [12]. A 36 amino acid peptide bind-
ing to the transmembrane glycoprotein gp41 inhibiting
the fusion of the viral envelope with the plasma mem-
brane is also used [13,14]. Two other classes of antiretro-
viral drugs, a CCR5 co-receptor antagonist entry inhibitor
[15] and an integrase inhibitor [16,17], have also recently
been approved. Other drugs being developed include zinc
finger inhibitors affecting the RNA binding of the nucleo-
capsid protein (NC, p7) [18,19], and capsid maturation
inhibitors [20-22].
We have previously shown that the tripeptide glycyl-pro-
lyl-glycineamide (GPG-NH2) cleaved to G-NH2 by dipep-
tidyl peptidase CD26, present in both human and fetal
calf serum, affects proper HIV-1 capsid assembly and
infectivity [23-26]. Here we show that G-NH2 by itself
does not affect HIV-1 replication, but displays antiviral
effect only when converted to a metabolite by a yet
uncharacterized enzyme present in porcine or bovine
serum but not in human serum. The metabolite was iden-
tified as the small molecule α-hydroxy-glycineamide (α-
HGA) having a molecular mass of only 90 Daltons, a mol-
ecule which we recently showed could inhibit HIV-1 rep-
lication [27].
Results
The effect of serum on the antiviral activity of 
glycineamide (G-NH2)
The antiviral activity of G-NH2  was tested in HIV-1
infected H9 cells cultured in medium containing human
(HS), porcine (PS) or fetal calf serum (FCS). When FCS
was used, 100 μM G-NH2 repeatedly abolished HIV infec-
tivity (Fig. 1A, FCS). Similar results were also obtained
when infected cells were cultured in PS (data not shown).
However, no antiviral activity was observed when the
infected cells were cultured in HS (Fig. 1A, HS). An expla-
nation for this could be that G-NH2 had to be converted
by an enzyme present in FCS and PS, but not in HS, to
acquire its antiviral activity. To test this hypothesis, 1 mM
G-NH2 was dialyzed against FCS (pre-dialyzed against PBS
five times to clear it from low molecular weight material)
at 37°C over night. The dialysis solution (DS) obtained
which contained the presumed G-NH2 metabolite, was
then added to infected H9 cells cultured in medium con-
taining HS (Fig. 1B, DS). Infected cell cultures to which
100 μM G-NH2 or no drug had been added served as con-
trols. The results of a typical experiment are shown in Fig.
1B. G-NH2 showed no antiviral activity, however, infected
cells cultured in human serum with DS at a 1/10 dilution,
corresponding to ~100 μM of possible G-NH2-FCS prod-
uct, showed virus replication that was completely inhib-
ited (Fig. 1B, DS).
To further test if G-NH2 was converted to the active antivi-
ral substance by an enzyme present in porcine or calf
serum, HIV-1-infected H9 cells were cultured in medium
containing normal PS or boiled PS (BPS). The cells were
then treated with 100 μM G-NH2, with the DS at a 1/10
dilution or were left untreated. A typical experiment is
depicted in Fig. 1C. Infected cells without any test com-
pound and cultured in medium containing PS or BPS
served as controls (Fig. 1C, Untreated). In contrast to what
was observed in cells cultured with BPS and treated with
DS, G-NH2 showed no antiviral activity in cells cultured
with medium containing BPS (Fig. 1C). DS, however,
repeatedly inhibited HIV replication regardless of the
infected cells being cultured in the presence of PS or BPS
(Fig. 1C, DS).
HPLC analysis of the unknown metabolite of G-NH2
DS derived from 1 mM G-NH2  dialyzed against pre-
washed HS or PS was analyzed by HPLC using a cationic
ion-exchange column. With G-NH2 dialyzed against PS at
37°C (Fig. 2A) but not at 4°C (Fig. 2B), a peak designated
Met-X (retention time at 2.9 min) was always observed in
addition to the G-NH2 peak (at 6.2 min). Dialysis of G-
NH2 in HS gave no such change in the HPLC pattern (Fig.
2C). The unknown peak fraction obtained by dialysis of
G-NH2 at 37°C was also isolated and tested for its antivi-
ral activity (see below).
Furthermore, we tested a number of different animal sera
for their ability to convert 14C-G-NH2 to the antiviral
metabolite X (Met-X). The conversion of G-NH2 to Met-X
was detected by the migration pattern in HPLC. As shown
in Figure 3, sera from human, rat, mouse, and bird did not
convert G-NH2 but sera from rabbit, monkey, cat, dog,
pig, horse and cow were successful in conversion.Retrovirology 2009, 6:34 http://www.retrovirology.com/content/6/1/34
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Identification of metabolite-X (Met-X) by NMR
13C2/15N-labeled glycine (Fig. 4A) was transformed to
13C2/15N-labeled G-NH2 (Fig. 4B) by Fmoc peptide syn-
thesis. In order to produce 13C2/15N-labeled Met-X (Fig.
4C),  13C2/15N-labeled G-NH2  (Fig. 4B) was dialyzed
against PS or FCS as described above. The 13C15N-labeled
Met-X was then purified by HPLC and the peak fraction
containing labeled Met-X was concentrated by lyophiliza-
tion before being analyzed by NMR.
Based on the NMR analysis (1H NMR, coupled 1H-13C
NMR, and 2D 1H-15N HSQC NMR) one of the possible
structures of the unknown compound Met-X was deter-
mined as α-hydroxy-glycineamide (α-HGA).
Antiviral activity of G-NH2 and characterization of G-NH2 metabolite obtained after dialysis against FCS or PS Figure 1
Antiviral activity of G-NH2 and characterization of G-NH2 metabolite obtained after dialysis against FCS or PS. 
(A) H9 cells (105) were infected with the SF-2 strain of HIV-1 and cultured in medium containing 100 μM G-NH2 and either 
10% fetal calf serum (FCS) or human serum (HS). Ten days post-infection, the level of p24-antigen in the culture supernatants 
was assayed with a p24-ELISA. (B) H9 cells infected with the SF-2 strain of HIV-1 were cultured in medium containing 10% 
human serum (HS) and either 100 μM G-NH2 or a dialysis solution (DS) of 1/10 dilution of 1 mM G-NH2 dialyzed against FCS. 
Untreated cultures without any addition of G-NH2 or DS served as controls. (C) Infected H9 cells were cultured in the pres-
ence of 10% boiled porcine serum (BPS) or non-boiled porcine serum (PS). The infected cultures were cultured with the addi-
tion of 100 μM G-NH2, DS or were left untreated. Virus production was assessed using an RT assay. Error bars indicate 
standard deviations from quadruple cultures.
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Comparison of Met-X with α-HGA
α-HGA was chemically synthesized and compared to Met-
X. The HPLC chromatogram of α-HGA was identical to
that of Met-X (Fig. 5A). Furthermore, the antiviral activity
of the HPLC peak fraction identified as Met-X and α-HGA
were tested in H9 cells infected with the HIV-1 SF-2 virus
and in chronically infected ACH-2 cells. Both substances
had similar antiviral activity (data not shown). The HPLC
peak fractions identified as Met-X and α-HGA were also
analyzed by capillary electrophoresis using bare silica cap-
illaries under the same experimental conditions. The anal-
ysis of Met-X revealed some impurities which were well
separated from the major peak containing Met-X (Fig.
5B). The pure α-HGA sample gave a symmetrical single
peak, which had strikingly similar migration times to Met-
X. The reproducibility was high (RSD = 1.14%; n = 4).
Comparison of the UV spectra of the substances in sepa-
rate experiments further revealed identical absorbance
properties. Furthermore, the structural information
gained by proton and carbon NMR analyses resulted in
identical chemical shift values (data not shown).
Both α-HGA and Met-X treatment at concentrations corre-
sponding to 10 μM resulted in similarly significant
changes in virion core morphology (data not shown). Ple-
omorphic virus particles with distorted, irregular packing
of aberrant core structures, partly devoid of dense core
material, were seen. Virions having double core structures
and occasionally viral cores bulging off from viral enve-
lope were also observed.
Anti-HIV activities of α-HGA and other related test 
compounds
α-HGA and some other structurally related compounds
(Fig. 6A) at drug concentrations of 100 μM were tested for
a possible inhibitory effect on HIV-1 replication in
infected H9 cells in the presence of FCS. As shown in Fig.
6B, both α-HGA and G-NH2 abolished HIV-1 replication.
By contrast, oxamic acid, oxamide, α-methoxy glycineam-
ide, and Boc-α-methoxy glycineamide did not show any
significant effect on HIV-1 replication. The 50% inhibi-
tory concentration (IC50) in HIV-1 SF-2 infected H9 cells
ranged from 4 to 6 μM for both α-HGA and Met-X. A typ-
ical dose response curve for α-HGA is depicted in Fig. 6C.
Discussion
In this study, we were able to identify, isolate and charac-
terize a novel antiretroviral glycineamide (G-NH2)-
derived metabolite (Met-X) obtained after incubation of
G-NH2 in porcine (PS) or fetal calf (FCS) serum. Dialysis
of G-NH2 against FCS at 4°C or boiled PS gave no Met-X,
indicating that the enzyme responsible for converting G-
NH2 to Met-X is temperature-dependent and heat-sensi-
tive. Furthermore, unlike in FCS or in PS, G-NH2 could
not be converted to Met-X when incubated in human
serum at 37°C, suggesting that humans lack either the
active enzyme or a necessary co-factor. Interestingly,
humans seem to share this inability to convert G-NH2
with mice, rats and birds. However, other species such as
non-human primates can readily convert G-NH2 to Met-X.
HPLC analysis of G-NH2 and the G-NH2-derived metabolite  Met-X Figure 2
HPLC analysis of G-NH2 and the G-NH2-derived 
metabolite Met-X. HPLC chromatograms of dialysis solu-
tion (DS) after dialyzing 1 mM G-NH2 against porcine serum 
(PS) at 37°C (A) and at 4°C (B) or human serum at 37°C. 
The dialysis solutions were analyzed with a cationic ion-
exchange column (Theoquest Hypersil SCX, Thermo), and 
the absorbance was measured at 206 nm.
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Conversion of G-NH2 to Met-X in different sera Figure 3
Conversion of G-NH2 to Met-X in different sera. 14C-labeled G-NH2 was incubated with sera from different species at 
different time points as indicated in the figure. Conversion to Met-X was analyzed by HPLC. Percent conversion to Met-X for 
respective sera is depicted.
0
10
20
30
40
50
60
70
80
90
100
%
 
C
o
n
v
e
r
s
i
o
n
 
o
f
 
[
1
4
C
]
G
-
N
H
2
 
t
o
 
[
1
4
C
]
D
-
H
G
A
human mouse rat avian rabbit simian feline canine porcine equine bovine
Serum
 1h
 6h
24h
Chemical structure and production of G-NH2-derived metabolite after dialysis against porcine serum Figure 4
Chemical structure and production of G-NH2-derived metabolite after dialysis against porcine serum. The 
chemical structures of doubly labeled glycine with two 13C- and one 15N-isotopes (A) which was transformed into labeled gly-
cineamide (B). The latter was dialyzed against porcine serum at 37°C, and the 13C2 
15N-labeled product (C) here is referred to 
as Met-X. This compound was purified by HPLC and concentrated before being analyzed with NMR.
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Here we characterized Met-X by NMR and this unknown
compound was identified as α-hydroxy-glycineamide (α-
HGA). In addition, with NMR, HPLC and capillary elec-
trophoresis analysis of Met-X and the synthesized α-
hydroxy-glycineamide the same chemical structure was
determined. Therefore, it is very likely that these two com-
pounds are identical chemical entities. The antiviral activ-
ity of the Met-X purified by cation exchange
chromatography and identified as α-HGA by NMR was
also confirmed both in H9 cells infected with the HIV-1
SF-2 virus and chronically infected ACH-2 cells. Consist-
ent with previous reports on GPG-NH2 and G-NH2, the
addition of Met-X or α-HGA to the culture medium of
infected cells resulted in HIV-1 particles with aberrant
core morphology.
The reduction in infectivity was not due to cytotoxicity,
since neither Met-X nor α-HGA at concentrations up to
1,000 μM has any effect on the cell viability of PBMC or a
number of other cell lines [27]. Furthermore, α-HGA had
no mitogenic activity against human PBMCs at concentra-
tions of up to 2,000 μM.
Two other compounds that inhibit or interfere with the
HIV-1 capsid (p24/CA) maturation or assembly have pre-
viously been reported [20,21,28]. PA-457 [20,22], is a
compound that binds to the proteolytic cleavage site of
the p24 precursor (p25/CA-SP1) and thereby affects its
maturation to p24. α-HGA does not affect the proteolytic
processing of p25 [27]. The other compound reported by
Tang et al. describes the binding of N-(3-chloro-4-methyl-
phenyl)-N'-2-(5-[dimethylamino-methyl]-2-furyl)-meth-
ylsulfanyl-ethyl urea (CAP-1) to the N-terminal domain
of p24 [21]. CAP-1 affects HIV-1 capsid cone formation
but did not prevent virus release [21]. However, α-HGA,
which is comparatively a small molecule, specifically
affected HIV-1 CA assembly and cone formation, possibly
by binding to the hinge region between the N- and C-ter-
minal domains of p24 [27]. A 12-mer alpha-helical pep-
tide (CAI) was also shown to interfere with p24
dimerization, but not with HIV-1 replication in cell cul-
ture due to the lack of cell penetration [28,29]. However,
more recently a structure-based rational design was used
to stabilize the alpha-helical structure of CAI and convert
Comparison of Met-X with α-HGA Figure 5
Comparison of Met-X with α-HGA. HPLC analysis of synthetically produced α-HGA and Met-X, the latter produced 
enzymatically after dialyzing 1 mM G-NH2 against PS at 37°C, is depicted in panel A, and capillary electrophoresis analysis of α-
HGA and Met-X in panel B.
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it to a cell-penetrating peptide (CPP) displaying antiviral
activity [30].
Conclusion
In this study, we have reported that G-NH2 by itself has no
anti-viral activity but is converted to a small (molecular
mass 90) anti-retroviral compound when incubated in
some animal sera. The new compound was identified as
α-HGA, which has an unusually simple structure and a
novel mechanism of antiviral action. Thus, α-HGA could
be a lead for new antiviral substances belonging to a new
class of anti-HIV drugs, i.e. capsid assembly/maturation
inhibitors.
Methods
Cells, media and reagents
Peripheral blood mononuclear cells (PBMC), H9 and
ACH-2 cells were cultured in complete RPMI-1640, and
HeLa-tat cells was cultured in complete DMEM medium
supplemented with 10% serum and antibiotics. Porcine
and human sera (PS and HS) (Biomeda), fetal calf serum
(FCS; Invitrogen) oxamic acid and oxamide (Sigma) were
used. Glycineamide (G-NH2) and α-hydroxy glycineam-
ide (α-HGA; manufactured to order by Pharmatory Oy,
Oulu, Finland) were kindly provided by Tripep AB, Stock-
holm, Sweden. 13C2/15N-labeled Fmoc-glycine (Isotech)
was transformed to 13C2/15N-labeled G-NH2 by Fmoc pep-
Biological and antiviral comparison of α-HGA and some structurally related compounds Figure 6
Biological and antiviral comparison of α-HGA and some structurally related compounds. Chemical structures of 
glycine, glycineamide (G-NH2), α-HGA, oxamic acid, oxamide, α-methoxy glycineamide and Boc-α-methoxy glycineamide (A). 
Antiviral activity of 100 μM of respective compound added to HIV-1 SF-2 infected H9 cells cultured in the presence of 10% 
fetal bovine serum (B). Dose response of the antiviral activity of synthetically produced α-HGA (C).
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tide synthesis. 13C2/15N-labeled G-NH2  was dialyzed
against PS or FCS to produce 13C2/15N-labeled metabolite
of G-NH2 which will be referred to as Met-X (Fig. 2A, B
and 2C).
Inhibition of viral infectivity
HIV-1 stock of SF-2 from H9 cells was prepared as
described previously [31], and 50% tissue culture infec-
tious dose (TCID50) was determined. H9 cells were
infected with SF-2 at 100 TCID50 by incubating for 2 hours
at 37°C. The cells were then pelleted, washed and resus-
pended in complete RPMI medium containing HS or PS,
and the test compound was added. Cells were cultured for
11 days, and the growth medium was changed seven days
post-infection. The HIV-1 p24 antigen contents were
assayed at day 7 and 11 post infection essentially as
described elsewhere [32] (see below). For RT-assay, the
manufacturer's procedure was followed (Cavidi Tech AB,
Uppsala, Sweden).
HPLC analysis and purification of Met-X
13C2/15N-labeled or unlabeled G-NH2 was enzymatically
transformed to Met-X by dialysis against FCS or PS at
37°C. Dialysis was performed with 10 ml of serum in a
dialysis tubing (5 kD MWCO) that was prewashed by dia-
lyzing 5× against PBS under constant stirring. After 24
hours, the dialysis solution (DS) containing Met-X was
analyzed by injecting it onto a 250 × 10 mm, 5 μm cati-
onic ion-exchange column, Theoquest Hypersil SCX,
(Thermo), with 90% 0.1 M KH2PO4pH 4.5/10% ace-
tonitrile as mobile phase at isocratic flow. The absorbance
was measured at 206 nm. Lyophilized 13C2/15N-labeled
Met-X was also analyzed as above except that a mobile
phase of 90% 2.5 mM formic acid pH 3/10% acetonitrile
was used. All HPLC chromatograms were compared using
retention time as an indicator. Once the structure of Met-
X was indicated by NMR (see below) to be α-HGA, the
HPLC properties of Met-X and chemically synthesized α-
HGA were analyzed under the same conditions.
Compound characterization by NMR spectroscopy
The HPLC peak fraction containing 13C2/15N-labeled Met-
X was isolated, lyophilized, and analyzed with NMR. Due
to the low natural abundance of 13C- and 15N-nuclei, a
commercially available labeled glycine with two 99% 13C-
and one 99% 15N-isotopes (Fig. 4A) was used as starting
material. The labeled glycine was transformed into G-NH2
(Fig. 4B) which was dialyzed against PS or FCS to obtain
labeled Met-X. The 13C/15N-labeled Met-X was purified by
HPLC and concentrated by lyophilization before being
analyzed with NMR. The samples were analyzed on a
Bruker DPX 300 MHz, a Jeol Eclipse+500 MHz and Bruker
DMX 600 MHz spectrometers.
Comparison of Met-X with α-HGA by capillary 
electrophoresis
Capillary electrophoresis experiments were carried out at
20°C with a BioFocus 3000 system (Bio-Rad) which was
equipped with a fast scanning UV-Vis detector. Fused sil-
ica tubing (50 and 365 μm inner and outer diameter,
respectively) was purchased from MicroQuartz and cut to
a length of 23 cm (with 18.5 cm effective length). Sodium
phosphate buffer (0.05 M) at pH 7.4 was used as a back-
ground electrolyte. The polarity was set from positive to
negative (with the detection point closer to the cathode).
The capillary was flushed with the buffer for 1 minute
before each run. The Met-X solution obtained from the
dialysis procedure was diluted two fold in the buffer solu-
tion and filtered through a syringe disc filter (Ultra free-
MC 5 000 NMWL, Millipore) prior to injection by pres-
sure (3 psi·s). α-HGA was dissolved in the buffer at 10
mM concentration and injected by pressure (3 psi·s). The
applied voltage was 10 kV in all experiments resulting in
50 μA current.
ELISA
p24-ELISA of infected cell culture supernatants was per-
formed essentially as described elsewhere [32]. Briefly,
rabbit anti-p24 coated micro-well plates (MWP) were
blocked with 3% BSA in PBS at 37°C for 30 minutes.
Supernatants from infected cells were added to the plates,
followed by incubated at 37°C for 1 hour. The MWPs
were washed three times, and biotinylated anti-p24 anti-
body (1:1 500) was added. One hour after incubation, the
MWPs were washed and incubated with HRP-conjugated
streptavidine (1:2 000) for 30 minutes. Finally, the MWPs
were washed and detected by adding the substrate o-Phe-
nylenediamine Dihydrochloride (Sigma). Recombinant
p24 at fixed concentrations was used as a standard. The
plates were read in a Labsystems multiscan MS spectrom-
eter. For RT-ELISA, the manufacturer's procedure was fol-
lowed (Cavidi Tech).
Anti-HIV activities of α-HGA and other related test 
compounds
The antiviral activity of α-HGA and some other structur-
ally related compounds was tested in infected H9 cells in
the presence of FCS at drug concentrations of 100 μM. H9
cells were infected as described above and cultured in
medium containing oxamic acid, oxamide, α-methoxy
glycineamide and Boc-α-methoxy glycineamide.
Conversion of G-NH2 to α-HGA by different sera
The sera from different animal species were diluted 10-
fold in 50 mM potassium phosphate buffer pH 8.0. To
100  μl (10% serum) were added 0.1 μCi [14C]G-NH2
(radiospecificity: 56 mCi/mmol), and the samples were
incubated for 1, 6 or 24 hours at 37°C. At these time
points, 200 μl cold methanol was added, and the samplesRetrovirology 2009, 6:34 http://www.retrovirology.com/content/6/1/34
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were left on ice for another 15 minutes. After centrifuga-
tion at 15,000 rpm, the supernatants were subjected to
HPLC analysis using a SCX-partisphere column (What-
man). The following gradient was used to separate G-NH2
and Met-X (α-HGA): 5 mM buffer B (5 mM NH4H2PO4
pH 3.5) (10 minutes); linear gradient to 83% buffer C
(0.3 M NH4H2PO4 pH 3.5) (6 minutes); equilibration
83% buffer C (2 minutes); linear gradient to 100% buffer
B (6 minutes); equilibration 100% buffer B (6 minutes).
The retention times of G-NH2 and α-HGA were 12 and 2
minutes, respectively.
Transmission electron microscopy (TEM)
H9 cells were infected with HIV-1 SF-2 at 100 TCID50 by
incubating for 2 hours at 37°C. After seven days of incu-
bation, medium containing Met-X or α-HGA was added.
Cells were cultured for an additional four days, and prog-
eny virus was analyzed by transmission electron micros-
copy (TEM). The HIV-1-infected H9 cells were fixed
freshly upon embedding in epon, essentially as described
before [24]. Sections were made approximately 60 nm
thick to allow accommodation of the volume of the core
structure parallel to the section plane. Duplicate samples
were used and minimal beam dose technique was
employed throughout. Evaluation of morphology was
done with series of electron micrographs to depict differ-
ent categories of virus morphology. Similar results were
also obtained with chronically infected ACH-2 cells
induced to replicate HIV-1.
Competing interests
Author AV is a shareholder and a director of the board of
Tripep AB, and author ML is an employee of Tripep AB.
Authors' contributions
SH performed electron microscopy, ÁV capillary electro-
phoresis, and ML HPLC analysis. MH together with WT
and IR performed NMR analysis. JB performed the exper-
iments with different animal sera. SA performed all other
experiments in the study and wrote the manuscript with
AV. AV is the principal investigator and conceived of the
study. All authors read and approved the manuscript.
Acknowledgements
We thank Pia Österwall and Sung Oun Stenberg for help with the dialysis 
and antiviral assay. We thank the original donors of the following reagents 
that were obtained through the AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH: the CD4+ cell lines H9 [33] and 
ACH-2 [34], and the CD4- cell line HeLa-tat-III [35]. This work was sup-
ported by grants from the K.U. Leuven (GOA-05/19), Swedish Research 
Council (grant no. K2000-06X-09501-10B), Swedish International develop-
ment Cooperation Agency, SIDA (grant no. HIV-2006-050) and Tripep AB.
References
1. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, Vogt VM,
Johnson MC: The stoichiometry of Gag protein in HIV-1.  Nat
Struct Mol Biol 2004, 11:672-675.
2. Lanman J, Lam TT, Barnes S, Sakalian M, Emmett MR, Marshall AG,
Prevelige PE Jr: Identification of novel interactions in HIV-1
capsid protein assembly by high-resolution mass spectrome-
try.  J Mol Biol 2003, 325:759-772.
3. Li S, Hill CP, Sundquist WI, Finch JT: Image reconstructions of
helical assemblies of the HIV-1 CA protein.  Nature 2000,
407:409-413.
4. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW
Jr, Sowder RC 2nd, Barsov E, Hood BL, Fisher RJ, et al.: Proteomic
and biochemical analysis of purified human immunodefi-
ciency virus type 1 produced from infected monocyte-
derived macrophages.  J Virol 2006, 80:9039-9052.
5. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sun-
dquist WI, Hill CP: Crystal structure of human cyclophilin A
bound to the amino-terminal domain of HIV-1 capsid.  Cell
1996, 87:1285-1294.
6. Momany C, Kovari LC, Prongay AJ, Keller W, Gitti RK, Lee BM, Gor-
balenya AE, Tong L, McClure J, Ehrlich LS, et al.: Crystal structure
of dimeric HIV-1 capsid protein.  Nat Struct Biol 1996, 3:763-770.
7. Berthet-Colominas C, Monaco S, Novelli A, Sibai G, Mallet F, Cusack
S: Head-to-tail dimers and interdomain flexibility revealed by
the crystal structure of HIV-1 capsid protein (p24) com-
plexed with a monoclonal antibody Fab.  Embo J 1999,
18:1124-1136.
8. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK,
Wang H, McCutcheon JP, Sundquist WI, Hill CP: Structure of the
carboxyl-terminal dimerization domain of the HIV-1 capsid
protein.  Science 1997, 278:849-853.
9. Forshey BM, von Schwedler U, Sundquist WI, Aiken C: Formation
of a human immunodeficiency virus type 1 core of optimal
stability is crucial for viral replication.  J Virol 2002,
76:5667-5677.
10. Mortuza GB, Haire LF, Stevens A, Smerdon SJ, Stoye JP, Taylor IA:
High-resolution structure of a retroviral capsid hexameric
amino-terminal domain.  Nature 2004, 431:481-485.
11. De Clercq E: The design of drugs for HIV and HCV.  Nat Rev
Drug Discov 2007, 6:1001-1018.
12. De Clercq E: Emerging anti-HIV drugs.  Expert Opin Emerg Drugs
2005, 10:241-273.
13. Root MJ, Steger HK: HIV-1 gp41 as a target for viral entry inhi-
bition.  Curr Pharm Des 2004, 10:1805-1825.
14. Yu H, Tudor D, Alfsen A, Labrosse B, Clavel F, Bomsel M: Peptide
P5 (residues 628–683), comprising the entire membrane
proximal region of HIV-1 gp41 and its calcium-binding site,
is a potent inhibitor of HIV-1 infection.  Retrovirology 2008, 5:93.
15. Groeschen HM: Novel HIV treatment approved.  Am J Health
Syst Pharm 2007, 64:1886.
16. Traynor K: Integrase inhibitor gains FDA approval.  2007,
64:2310.
17. Anker M, Corales RB: Raltegravir (MK-0518): a novel integrase
inhibitor for the treatment of HIV infection.  2008, 17:97-103.
18. Darlix JL, Garrido JL, Morellet N, Mely Y, de Rocquigny H: Proper-
ties, functions, and drug targeting of the multifunctional
nucleocapsid protein of the human immunodeficiency virus.
Adv Pharmacol 2007, 55:299-346.
19. Musah RA: The HIV-1 nucleocapsid zinc finger protein as a
target of antiretroviral therapy.  Curr Top Med Chem 2004,
4:1605-1622.
20. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C,
Castillo A, Zoumplis D, Martin DE, Orenstein JM, et al.: PA-457: a
potent HIV inhibitor that disrupts core condensation by tar-
geting a late step in Gag processing.  Proc Natl Acad Sci USA 2003,
100:13555-13560.
21. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang
M, Summers MF: Antiviral inhibition of the HIV-1 capsid pro-
tein.  J Mol Biol 2003, 327:1013-1020.
22. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, All-
away GP, Martin DE: Phase I and II study of the safety, virologic
effect, and pharmacokinetics/pharmacodynamics of single-
dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat)
against human immunodeficiency virus infection.  Antimicrob
Agents Chemother 2007, 51:3574-3581.
23. Su J, Andersson E, Horal P, Naghavi MH, Palm A, Wu YP, Eriksson K,
Jansson M, Wigzell H, Svennerholm B, Vahlne A: The nontoxic
tripeptide glycyl-prolyl-glycine amide inhibits the replicationPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2009, 6:34 http://www.retrovirology.com/content/6/1/34
Page 10 of 10
(page number not for citation purposes)
of human immunodeficiency virus type 1.  J Hum Virol 2001,
4:1-7.
24. Hoglund S, Su J, Reneby SS, Vegvari A, Hjerten S, Sintorn IM, Foster
H, Wu YP, Nystrom I, Vahlne A: Tripeptide interference with
human immunodeficiency virus type 1 morphogenesis.  Anti-
microb Agents Chemother 2002, 46:3597-3605.
25. Balzarini J, Andersson E, Schols D, Proost P, Van Damme J, Svenner-
holm B, Horal P, Vahlne A: Obligatory involvement of CD26/
dipeptidyl peptidase IV in the activation of the antiretroviral
tripeptide glycylprolylglycinamide (GPG-NH(2)).  Int J Biochem
Cell Biol 2004, 36:1848-1859.
26. Andersson E, Horal P, Jejcic A, Hoglund S, Balzarini J, Vahlne A, Sven-
nerholm B: Glycine-amide is an active metabolite of the
antiretroviral tripeptide glycyl-prolyl-glycine-amide.  Antimi-
crob Agents Chemother 2005, 49:40-44.
27. Abdurahman S, Vegvari A, Youssefi M, Levi M, Hoglund S, Andersson
E, Horal P, Svennerholm B, Balzarini J, Vahlne A: Activity of the
small modified amino acid alpha-hydroxy glycineamide on in
vitro and in vivo human immunodeficiency virus type 1 cap-
sid assembly and infectivity.  Antimicrob Agents Chemother 2008,
52:3737-3744.
28. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, Dietrich U,
Werner J, Krausslich HG: A peptide inhibitor of HIV-1 assembly
in vitro.  Nat Struct Mol Biol 2005, 12:671-677.
29. Ternois F, Sticht J, Duquerroy S, Krausslich HG, Rey FA: The HIV-1
capsid protein C-terminal domain in complex with a virus
assembly inhibitor.  Nat Struct Mol Biol 2005, 12:678-682.
30. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A,
Heck S, Curreli F, Goger M, Cowburn D, et al.: A cell-penetrating
helical peptide as a potential HIV-1 inhibitor.  J Mol Biol 2008,
378:565-580.
31. Vahlne A, Horal P, Eriksson K, Jeansson S, Rymo L, Hedstrom KG,
Czerkinsky C, Holmgren J, Svennerholm B: Immunizations of
monkeys with synthetic peptides disclose conserved areas
on gp120 of human immunodeficiency virus type 1 associ-
ated with cross-neutralizing antibodies and T-cell recogni-
tion.  Proc Natl Acad Sci USA 1991, 88:10744-10748.
32. Horal P, Hall WW, Svennerholm B, Lycke J, Jeansson S, Rymo L, Kap-
lan MH, Vahlne A: Identification of type-specific linear epitopes
in the glycoproteins gp46 and gp21 of human T-cell leukemia
viruses type I and type II using synthetic peptides.  Proc Natl
Acad Sci USA 1991, 88:5754-5758.
33. Popovic M, Sarngadharan MG, Read E, Gallo RC: Detection, isola-
tion, and continuous production of cytopathic retroviruses
(HTLV-III) from patients with AIDS and pre-AIDS.  Science
1984, 224:497-500.
34. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Bar-
stad P, Kovacs J, Fauci AS, Folks TM: Monokine regulation of
human immunodeficiency virus-1 expression in a chronically
infected human T cell clone.  J Immunol 1989, 142:431-438.
35. Rosen CA, Haseltine WA, Lenz J, Ruprecht R, Cloyd MW: Tissue
selectivity of murine leukemia virus infection is determined
by long terminal repeat sequences.  J Virol 1985, 55:862-866.